Medicine reference
Tesamorelin
A source-linked medicine reference on Tesamorelin, its documented context and safety boundaries. Sources checked 6 September 2026.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 March 2027.
Identity and scope
Tesamorelin is a prescription growth-hormone-releasing-factor analogue. It is distinct from growth hormone and from general fat-loss products.
Sources: MedlinePlus / American Society of Health-System Pharmacists
Documented context
The cited monograph describes reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It does not establish a general weight-loss or body-composition claim.
Sources: MedlinePlus / American Society of Health-System Pharmacists
Safety and a useful record
The medicine’s endocrine and glucose context requires clinician monitoring. Product identity and the diagnosed indication matter.
Sources: MedlinePlus / American Society of Health-System Pharmacists
Record the prescription, HIV-care team plan, glucose context and adverse effects.
Published sources
- Tesamorelin injection
MedlinePlus / American Society of Health-System Pharmacists. Current ASHP consumer monograph; accessed 6 September 2026.
Supports: HIV-associated lipodystrophy context and safety information.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.